These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2876770)

  • 1. Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. The Ludwig Lung Cancer Study Group (LLCSG).
    Cancer; 1986 Dec; 58(11):2411-6. PubMed ID: 2876770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term evaluation of intrapleural bacillus Calmette-Guerin with or without adjuvant chemotherapy in completely resected stages II and III non-small-cell lung cancer.
    Macchiarini P; Hardin M; Angeletti CA
    Am J Clin Oncol; 1991 Aug; 14(4):291-7. PubMed ID: 1650528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrapleural and intravenous Corynebacterium parvum in patients with resected stage I and II non-small cell carcinoma of the lung. The Ludwig Lung Cancer Study Group.
    Ludwig Lung Cancer Study Group
    Cancer Immunol Immunother; 1986; 23(1):1-4. PubMed ID: 2876772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. Preliminary report of the National Cancer Institute Lung Cancer Study Group.
    J Thorac Cardiovasc Surg; 1981 Nov; 82(5):649-57. PubMed ID: 7029149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. LCSG Protocol 771.
    Gail MH
    Chest; 1994 Dec; 106(6 Suppl):287S-292S. PubMed ID: 7988246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer.
    McKneally MF; Maver C; Lininger L; Kausel HW; McIlduff JB; Older TM; Foster ED; Alley RD
    J Thorac Cardiovasc Surg; 1981 Apr; 81(4):485-92. PubMed ID: 7009993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparison of the effects of adjuvant therapy on resected stages II and III non-small cell carcinoma of the lung. The Lung Cancel Study Group.
    Holmes EC; Hill LD; Gail M
    Ann Surg; 1985 Sep; 202(3):335-41. PubMed ID: 3899029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional immunotherapy with intrapleural BCG for lung cancer.
    McKneally MF; Maver C; Kausel HW; Alley RD
    J Thorac Cardiovasc Surg; 1976 Sep; 72(3):333-8. PubMed ID: 785107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complications of postoperative intrapleural BCG in lung cancer.
    Bakker W; Nijhuis-Heddes JM; Brutel de la Rivière A; Dijkman JH
    Ann Thorac Surg; 1982 Mar; 33(3):267-72. PubMed ID: 7073367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified stage I (T1N0M0, T2N0M0), nonsmall cell lung cancer: treatment results, recurrence patterns, and adjuvant immunotherapy.
    Little AG; DeMeester TR; Ferguson MK; Skinner DB; Hoffman PC; Skosey C; Blough RR; Golomb HM
    Surgery; 1986 Oct; 100(4):621-8. PubMed ID: 3020725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
    Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
    Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin.
    Yasumoto K; Manabe H; Yanagawa E; Nagano N; Ueda H; Hirota N; Ohta M; Nomoto K; Azuma I; Yamamura Y
    Cancer Res; 1979 Aug; 39(8):3262-7. PubMed ID: 222448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report.
    Bakker W; Nijhuis-Heddes JM; van der Velde EA
    Cancer Immunol Immunother; 1986; 22(2):155-9. PubMed ID: 3719595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralesional BCG injection of pulmonary neoplasms: radiographic findings.
    Fon GT; Bein ME; Holmes EC; Huberman RP
    AJR Am J Roentgenol; 1981 Aug; 137(2):269-75. PubMed ID: 6789633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse reactions to intrapleural BCG.
    N Engl J Med; 1981 Jul; 305(3):167-8. PubMed ID: 6264294
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
    Keller SM; Adak S; Wagner H; Herskovic A; Komaki R; Brooks BJ; Perry MC; Livingston RB; Johnson DH
    N Engl J Med; 2000 Oct; 343(17):1217-22. PubMed ID: 11071672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumonectomy: calculable or non-tolerable risk factor in trimodal therapy for Stage III non-small-cell lung cancer?
    Steger V; Spengler W; Hetzel J; Veit S; Walker T; Mustafi M; Friedel G; Walles T
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):880-5; discussion 885. PubMed ID: 22233799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.